finance.yahoo.com ·
supernus pharmaceuticals inc q1 2026 001910629
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedSupernus Pharmaceuticals, a US-based specialty pharma company, reported strong Q1 2026 results driven by ADHD drug Qelbree and Parkinson's drug GOCOVRI. Revenue growth is product-specific, not sector-wide. The company plans to file for a second supplier of Onepco (active ingredient for Qelbree) to mitigate supply risk. No direct impact on broader pharma sector or other companies. Commercial mechanism is company-specific revenue and margin improvement, with supply chain diversification for a key input.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Supernus Q1 2026 revenue up 56% YoY
- Qelbree net sales growth 20% YoY, adult prescriptions up 27%
- Full-year revenue guidance $840M-$870M
- GAAP net loss improved to $2.3M from $11.8M
- Regulatory submission for second Onepco supplier expected Q3 2026
Supernus' Q1 2026 results may lift sentiment for Qelbree and GOCOVRI in the next week, with a 1-2% upward move expected.
Sign in to see all sector verdicts, full thesis and counter-argument debate.